Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Grabar S, et al. Among authors: allavena c. HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x. HIV Med. 2008. PMID: 18366449 Free article.
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group. Allavena C, et al. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6. doi: 10.1097/01.qai.0000165914.42827.bb. J Acquir Immune Defic Syndr. 2005. PMID: 15980689 Clinical Trial.
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team. Valantin MA, et al. Among authors: allavena c. HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8. HIV Med. 2008. PMID: 18624724 Free article. Clinical Trial.
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, El Guedj M, de la Tribonnière X, Valantin MA, Dellamonica P; Nadis Group. Pugliese P, et al. Among authors: allavena c. HIV Med. 2009 Sep;10(8):504-11. doi: 10.1111/j.1468-1293.2009.00719.x. Epub 2009 May 19. HIV Med. 2009. PMID: 19486189 Free article.
Risk factors of chronic kidney disease in HIV-infected patients.
Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabié A, Poizot-Martin I, Katlama C, Brunet-François C, Yazdanpanah Y, Dellamonica P; New AIDS Data group. Flandre P, et al. Clin J Am Soc Nephrol. 2011 Jul;6(7):1700-7. doi: 10.2215/CJN.09191010. Epub 2011 May 12. Clin J Am Soc Nephrol. 2011. PMID: 21566114
239 results